Mangoceuticals, Inc. cash flow to debt ratio of -1.90K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Mangoceuticals, Inc.'s free cash flow has decreased 20.28% from $-4.86M last year to $-5.85M, signaling decreasing performance

Mangoceuticals, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Mangoceuticals, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.02 today, signaling weakened financials

Mangoceuticals, Inc. has a net cash position, so leverage is healthy.

Mangoceuticals, Inc.'s interest coverage ratio is -44.23, which means that the company struggles to meet interest obligations, signaling financial risk.

Mangoceuticals, Inc.'s profit margin has decreased (227.74%) in the last year from -1.41K% to -4.63K%, signaling decreasing performance

Mangoceuticals, Inc.'s short-term assets of $1.55M exceed its short-term liabilities of $890.57K

Mangoceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Mangoceuticals, Inc.'s return on equity of -120.71%, is lower than 15.00%, indicating bad performance

Mangoceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Mangoceuticals, Inc. has insufficient public price history to evaluate earnings stability.

Mangoceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Mangoceuticals, Inc. has negative free cash flow, indicating cash burn

Mangoceuticals, Inc.'s yearly earnings has decreased 137.12% since last year from $-8.71M to $-20.64M, signaling decreasing performance

Mangoceuticals, Inc.'s yearly revenue has decreased 50.51% since last year from $615.87K to $304.81K, signaling decreasing performance

ROIC -126.58% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Mangoceuticals, Inc.'s 3-year revenue CAGR of 270.88% is positive, indicating growing revenue over the past 3 years

Mangoceuticals, Inc. has insufficient public price history to evaluate revenue consistency.

Mangoceuticals, Inc. has insufficient public price history to evaluate ROE consistency.

Mangoceuticals, Inc. has insufficient data to evaluate this check.

Mangoceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mangoceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Mangoceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Mangoceuticals, Inc. has insufficient data to evaluate this check.

Mangoceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mangoceuticals, Inc. has a price-to-book ratio of 0.44x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Mangoceuticals, Inc. has a price-to-sales ratio of 14.43x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue